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This thesis examines and evaluates the manipulation of the microbiota as an immune-modulating 
therapy for improving the outcomes of solid organ transplants by helping prevent organ 
rejection, infection, and chronic disease development. Focusing on kidney, liver, and heart 
transplants, the factors contributing to gut dysbiosis before, during, and after solid organ 
transplant are analyzed and solutions to restore homeostasis to the gut microbiome, including 
fecal microbial transplant, synbiotic therapy, short chain fatty acid supplementation, diet and 
exercise interventions, and a sub-specialized transplant ICU are evaluated for their potential 
success in altering the human gut microbiome and preventing allograft rejection and the 
development of chronic diseases. These therapies are also evaluated in terms of cost, amount of 
care they require, and the challenges they face. This research was conducted through reviewing 
primary research papers and conducting interviews with faculty at Dell Medical School and the 
University of Texas School of Nursing. It concludes that without full understanding of the 
microbiome's role in health and disease it is too early to determine an approach for restoring 
homeostasis to the human microbiome. However, it is likely that there will not be just one 
solution to restoring a disrupted microbiome and that individual microbial differences will play a 
large role in determining the method and success of microbiome manipulation. Currently, diet 
and exercise programs are the most cost effective and safest therapeutic strategies and should be 
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Health and disease are profoundly influenced by diverse microbial communities known 
collectively as the microbiome. The human microbiome refers to the complex community of 
commensal and pathogenic microorganisms that exist in the nonsterile sites of the body. Half of 
the genes in an individual’s intestinal microbiome have been found to be unique to the 
individual, demonstrating the innate variability of the gut microbiome. Vast individual microbial 
differences impede our understanding of how the intestinal microbiome regulates health, 
specifically in terms of immune system regulation and protection from pathogenic organisms. 
This lack of knowledge limits the ability of doctors to manipulate the intestinal microbiome for 
the patient’s benefit.  
Solid organ transplant patients experience a significant shift in the diversity and 
dominance of bacterial populations that constitute their intestinal microbiome, both before and 
after the transplant procedure. This shift often results in a microbial imbalance, referred to as 
dysbiosis. While it is not quite understood how, the gut microbiome is an important modulator of 
the immune system such that gut dysbiosis has been found to increase patients’ risk of infection.  
This is a serious issue since patients must comply with strict immunosuppression medication 
after their transplant to prevent organ rejection. Furthermore, immunocompromised patients are 
at a heightened risk for developing chronic diseases such as type one and type two diabetes, 
cancer, and high blood pressure, all of which the gut microbiome plays a role in regulating. 
Developing any one of these chronic diseases increases health risks for the patient. The current 
risk for organ rejection, post-transplant infection, and chronic disease development in solid organ 
transplant patients makes the development of therapies to restore homeostasis to the intestinal 
microbiome critical to the future success of solid organ transplants.   
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This thesis advocates for the manipulation of the microbiota as an immune-modulating 
therapy to improve solid organ transplant outcomes through the prevention of organ rejection 
and chronic disease development by analyzing current methods for restoring homeostasis in the 
human gut microbiome and by making recommendations on how to reduce disruptions to the 
microbiome before, during, and after transplant. Kidney, liver, and heart transplants will be 
studied as they are the most commonly performed types of solid organ transplants. The effects of 
kidney, liver, and heart solid organ transplant on the human gut microbiome will be examined, as 
will the ways in which the preparation for solid organ transplant, the solid organ transplant 
procedure, and recovery protocols for solid organ transplants affect patients’ gut flora. Current 
solutions for re-establishing homeostasis in the human gut microbiome including fecal 
microbiota transplant (FMT), short-chain fatty acid supplementation, synbiotic therapy, dietary 
and exercise changes, and the creation of a sub-specialized transplant ICU will be evaluated for 
their potential success in altering the human gut microbiome, reducing allograft rejection in solid 
organ transplant patients, and preventing the development of comorbidities. These therapies will 
be analyzed in terms of their predicted outcome, cost, the amount of care required, and the 










Chapter 1- Solid Organ Transplants and the Microbiome 
 
I.  Solid Organ Transplantation 
The field of solid organ transplants, although relatively new, has seen much progress in 
the 60 years since its origin. While it began as an experimental procedure, it has quickly evolved 
into a life-saving operation that saved 33,175 lives in 2019 (UNOS). A solid organ transplant is 
an operation in which an organ is surgically removed from its donor and transplanted into a 
recipient who suffers from irreversible and otherwise fatal organ failure. Transplants are 
necessary and lifesaving for the recipient. Today, there are nine types of organ transplants that 
are performed: kidney, lung, heart, liver, pancreas, skin, cornea, trachea, and vascular tissue.  
To receive an organ transplant, potential transplant patients must be referred by a primary 
care physician and a specialist. The requirements to qualify for an organ transplant differ 
depending on the type of transplant needed. However, in all cases, the patient must meet strict 
medical criteria. The patient must not suffer from multiple-organ failure, have a persistent or 
pervasive infection, or have any other option as an alternative to organ transplant. Additionally, 
the patient’s medical status and psycho-social factors are analyzed by a transplant center team to 
make sure the recipient patient will survive the procedure and benefit from a transplanted organ. 
This evaluation is difficult because a patient’s medical status is constantly changing. 
Furthermore, the transplant team must evaluate the patient’s mental health, how likely the patient 
would be to follow the strict lifelong regimen of anti-rejection drugs, and the likelihood of 
compliance with follow-up appointments and post-surgical interventions if necessary. The 
purpose of these evaluations is to ensure the organ will have the greatest chances for success in 
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the patient and to make sure the patient’s quality of life is enhanced enough to compensate for 
the rigorous transplant surgery and post-transplant care regimen. 
Once patients have been evaluated and placed on the waitlist for an organ transplant, they 
wait to be matched to an organ. When an organ becomes available, patients who match the 
medical and biological profile of the donor are ranked. This ranking takes into consideration how 
long the patient has been on the waiting list as well as their location. The transplant center is 
contacted when an organ becomes available and the transplant team considers the organ for the 
patient. The transplant team either accepts or declines it based on organ condition, patient 
condition, staff availability, and organ transportation. The transplant waiting list is necessary due 
to the lack of available organs and the high demand for them worldwide. Currently, 114,000 
people are on the waiting list for an organ donation and 20 people die each day waiting for an 
organ to become available (UNOS).  
The high demand for organs and lack of supply is still the biggest challenge in improving 
the success of organ transplants. As researchers continue looking for ways to increase organ 
supply, such as 3D printing organs from cultured human cells, the best way to improve the 
success of organ transplants is to maximize organ functionality after the time of surgery. 
However, long term survival rates have not improved and the chances of surviving 5 to 20 years 
after having a transplant procedure are still not significantly different for a 1980s-era patient than 
a present-day organ recipient (Rana, Abbas, & Godfrey, 2019). Infection and graft failure are 
still the main causes of death with death from malignancy increasing over time (Rana, Abbas, & 
Godfrey, 2019). 
Researchers have focused on improving long term organ function through improvements 
in immunosuppressive therapies. Immunosuppressive drugs are essential for organ transplant 
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patients to ensure the recipient does not reject the allograft. An allograft is the transplant of an 
organ from one individual to another who is of the same species, but has a different genotype. 
Allograft rejection is a complex response that involves multiple cell types and cell mediators. 
The process of organ rejection is initiated by the presence of histocompatibility antigens. 
Antigens are foreign substances that induce an immune response in the body. Antibodies, 
protective proteins that neutralize and bind to antigens, are produced by B cells and operate to 
prevent antigens from penetrating body cells. They also mark antigens for removal from the 
body.  
The major histocompatibility complex (MHC), found on chromosome six, is a group of 
genes that code for proteins located on the surface of cells that help the immune system identify 
foreign substances (Janeway et al., 2001). The MHC produces two classes of protein molecules, 
class I and class II proteins, which present antigenic peptides so T cells can recognize them. T 
cells play an important role in organ rejection in that they recognize antigens presented by MHC 
proteins. CD8 T cells recognize antigenic peptides from within the cell presented by MHC class I 
proteins while CD4 T cells recognize extracellular antigenic peptides presented by MHC class II 
proteins (Janeway et al., 2001). During organ rejection, CD4 and CD8 T cells recognize antigens 
expressed on the cells of the foreign graft.  
         Solid organ rejection occurs by two different pathways. In one pathway, called the direct 
pathway, T cells (CD4 and CD8) recognize foreign MHC molecules (class I and II proteins) on 
donor antigen-presenting cells. This is believed to be the main pathway in acute organ rejection. 
The other pathway, known as the indirect pathway, functions by T cells recognizing allopeptides 
on recipient MHC molecules (Bharat & Mohanakumar, 2007). Dendritic cells play a major role 
in the graft induced immune response and are involved in both rejection pathways. Dendritic 
10 
 
cells (DCs) specialize in the capture and processing of antigens and are abundant in organs and 
peripheral tissues so they can capture antigens (Roghanian). In the direct pathway, DCs migrate 
from the graft and into secondary lymphoid tissues where they activate T cells (Ingulli, 2010). In 
the indirect pathway, graft proteins are processed by the DCs which are then presented to T-cells. 
A study that examined the indirect and direct rejection pathways in mice concluded that the 
direct alloresponse was short-lived and the indirect alloresponse became the main pathway in 
long term graft rejection (Benichou et al., 2017). This implies that by targeting and controlling 
the indirect allorecognition pathway, graft rejection can be prevented. 
Immunosuppressants act to prevent the immune system from recognizing foreign MHC 
molecules and allopolypeptides by suppressing the immune system, specifically targeting T cells, 
B cells, anti-donor antibodies, and other immune system molecules (Hartono, Muthukumar, 
Suthanthiran, 2013). They are classified as either induction or maintenance agents. Induction 
agents work to prevent acute rejection while maintenance agents prevent long term rejection. The 
introduction of new maintenance agents, calcineurin inhibitors (CNI), cyclosporine (CsA), and 
tacrolimus (Tac), in the 1980s resulted in improved graft outcome (Hartono, Muthukumar, 
Suthanthiran, 2013). Calcineurin inhibitors inhibit the action of calcineurin, an enzyme that 
stimulates T cells. Other immunosuppressive agents such as small molecules, biologics, 
Mycophenolate Mofetil (MMF), Sirolimus, Rabbit antithymocyte globulin (rATG), 
Alemtuzumab, and Belatacept have recently become available for clinical use (Hartono, 
Muthukumar, Suthanthiran, 2013). However, increased potency of newer immunosuppressive 
agents can increase the risk of polyomavirus infection and post-transplant EBV-associated 
lymphoma (Hartono, Muthukumar, Suthanthiran, 2013). The implementation of these 
11 
 
immunosuppressive drugs has helped improve short term outcomes in organ transplant patients, 
but have not improved the life span of the transplanted organ long term.  
 
II.  The Human Microbiome 
The human microbiome refers to the community of microorganisms and their genes that 
exist in the nonsterile sites of the body, such as the skin, respiratory tract, and gastrointestinal 
tract (Hair & Sharpe). Everyone carries their own microbial communities, shaped by mode of 
birth, environment, genetics, diet, and other lifestyle and biological factors. Since the discovery 
of the microbiome in the late 1990s, scientists have predicted that there are over 100 trillion 
microbes living in humans, with the majority residing in the gut, specifically the large intestine 
(Hair & Sharpe). With this many microbes living in humans, the total number of genes in the 
microbiome is 200 times greater than the number of genes in the human genome. In addition, 
half of the genes in an individual’s microbiome have been found to be unique to the individual 
(Ursell et al., 2012). This positions bacteria to be a powerful modulator of health and disease.  
The microbiome acts as its own ecosystem separate from the human body and is 
considered an environmental factor that influences health and disease. Microbes live in 
symbiosis with their human host and are variable and unique to everyone. The intestinal 
microbiome is primarily made up of bacteria from the genus Bacteroides which includes 
Peptostreptococcus, Eubacterium, Lactobacillus, and Clostridium (Rowland et al., 2018). Most 
of the bacteria that make up the microbiome are not harmful, but beneficial. These microbial 
communities play essential roles in metabolism, food digestion, and immune system regulation. 
Communication networks between intestinal microbes at mucosal membranes and the 
host have a large impact on the development of the immune system. This has been observed 
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through studies comparing germ-free and conventional animals. The results of these studies 
show that intestinal microbes are essential for the proper function and development of the 
mucosal immune system in early stages of life (Purchiaroni et al., 2013). This has a critical 
impact on lifelong immunity in adults. In addition, it has been found that the composition of the 
intestinal microbiome impacts gut-associated lymphoid tissue (GALT) which consists of isolated 
or aggregated lymphoid follicles which form Peyer's patches, groupings of lymphoid follicles 
that contain a variety of immune cells which provide immune surveillance in the digestive 
system (Seladi-Schulman). GALT contains around 70% of the body’s immunocytes, cells that 
can induce an immune response by creating antibodies (Jung, Hugot, & Barreau, 2010). Defects 
in GALT development, a reduced cellular lamina propria, fewer plasma cells in the germinal 
center of the mesenteric lymph nodes (MLNs), and a reduction in antibody production and the 
number of Peyer’s patches were all observed in germ-free animals compared to animals under 
normal conditions (Jung, Hugot, & Barreau, 2010). While the immune system is highly impacted 
by the microbial ecosystem in the gut, microbes themselves are affected by many factors. Altered 
gut microbiota can directly and indirectly affect immune cells in the gut. 
Intestinal microbial composition is shaped by many external and genetic factors. The 
composition of the microbiome has been found to be more similar among blood relatives than 
unrelated individuals suggesting that the composition of the microbiome is influenced by genetic 
factors. However, external factors, such as diet, lifestyle, stress levels, and medications taken 
have been found to be more influential determinants of microbiome composition. Beginning as 
early as birth, an infant's method of delivery has been found to be an external factor that affects 
the early establishment of an infant's microbiome. Infants born by vaginal birth are exposed to 
their mothers' bacteria which affects the development of the infant’s gut bacteria and stimulates 
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the immune system (Wen & Duffy., 2017). Infants delivered by cesarean section lack early 
exposure to bacteria which puts them at a higher risk for type two diabetes and obesity (Wen & 
Duffy., 2017). Breastfeeding too affects the development of an infant’s microbiome. Breast milk 
contains commensal bacteria and probiotics that provide essential nutrients to the infant and 
influence the development of an infant’s gut bacteria (Wen & Duffy., 2017). Breast milk from 
obese mothers has been found to lack diversity in bacteria compared to breast milk from normal-
weight mothers. These findings show that the transfer of microbes from mothers to their infants 
is an external factor that affects infant growth, microbiota development, and health. 
Another factor affecting the composition of the microbiome is the use of antibiotics and 
other medications. Antibiotics, used to treat bacterial infections, have an impact on the 
composition of the intestinal microbiome by reducing the diversity of bacteria in the microbiome 
and enabling resistant strains to overgrow and dominate (Wen & Duffy., 2017). Clindamycin, an 
antibiotic used to treat bacterial infections of the skin, internal organs, lungs, and blood, in young 
children has been found to have a negative long term effect on the composition of the gut 
microbiome by reducing the microbiome’s resistance to colonization by pathogens and 
disturbing normal bowel function (Dudek-Wicher, Junka, & Bartoszewicz, 2018). Other 
antibiotic groups such as fluoroquinolones and β-lactams have the same effect of decreasing the 
diversity in the microbiota (Dudek-Wicher, Junka, & Bartoszewicz, 2018). However, the amount 
of variation in microbiota diversity depends on the initial bacterial profile of the individual’s 
microbiome. Antibiotic treatment also affects the microbiome by liberating fucose and sialic 
acid, mucosal carbohydrates. An increased level of these substances presents pathogens such as 
Salmonella typhimurium and C. difficile with the opportunity to colonize the gut (Dudek-Wicher, 
Junka, & Bartoszewicz, 2018). Non-antibiotic drugs have also been associated with changes in 
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composition and function of gut microbiome composition. Proton pump inhibitors, metformin, 
antibiotics, and laxatives have been found to have the biggest impact on microbiota composition. 
Non-antibiotic drugs were found to increase upper GI tract bacteria, fatty acid production, E. coli 
levels, and antibiotic resistance mechanisms in the gut microbiome (Vich Vila et al., 2019). 
Diet also has a major impact on the composition of the gut microbiome. High fat and 
sugar diets correlate to fewer bacterial species in the intestinal microbiome and cause dysbiosis, 
microbial imbalance, in the microbiome. This puts individuals who eat a high fat and sugar diet 
at a higher risk for disease such as inflammatory bowel disease. In contrast, diets rich in complex 
carbohydrates have shown an increase in gut microbiome diversity (Schnorr et al., 2016). Fiber 
rich diets help regulate the microbiome and have been found to restore levels of beneficial 
microbes and lower the number of harmful microbial metabolites. It also increases the number of 
short chain fatty acids (SCFAs) produced which help stabilize the microbiome and can protect 
against colorectal cancer and inflammation (Louis et al, 2014). 
Exercise promotes diversity of microbes in the gut. Data from a study conducted on 
professional rugby players showed that exercise positively influences the diversity in the 
microbiome by increasing the amount of diversity among the Firmicutes phylum indicating a 
healthier intestinal environment. In addition, protein intake and creatine kinase levels also 
increased. Another study, which examined different levels of cardiorespiratory fitness, found that 
cardiorespiratory fitness was correlated to a more diverse microbiome (Monda et al., 2017). 
Cardiorespiratory fitness is defined as the ability of the circulatory, respiratory, and muscular 
systems to supply oxygen throughout the body during sustained physical activity (Lee et al., 
2010). Higher levels of exercise and fitness correlated with enriched butyrate-producing taxa in 
the microbiome. Butyrate production is an indicator of good gut health. 
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While the microbiome is influenced by genetic factors and events at birth, its composition 
is variable and predominantly affected by many lifestyle choices and external factors. The 
variability of the microbiome makes it a good target to manipulate to improve an individual's 
overall health. However, the microbiome can just as easily be negatively affected by external 
factors as well, making it a tricky target.  
After solid organ transplantation, the microbiota in the gut and other body sites changes. 
The change in the microbiome is different depending on the type of solid organ transplant and 
varies greatly among individuals. In liver transplant recipients, there is a post-transplant 
reduction in the amount of Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii 
present in fecal samples, but an increased number of bacteria from the family Enterobacteriaceae 
(Wu et al., 2012). While in lung transplant recipients, there is an increase in the number of 
bacteria and fungi in the lower respiratory tract, but a decrease in the diversity of bacteria and 
fungi (Charlson, 2012). These changes have been associated with acute and chronic graft 
rejection which suggests that the microbiota has an impact on alloimmunity and transplant 
outcome. It has been found that different microbial community structures have different effects 
on transplant outcome such that some microbiota community structures increase alloimmunity 
and accelerate rejection, some community structures have neutral effects on graft rejection, and 
others dampen transplant rejection (Sepulveda et al., 2019).  
The role that the human gut microbiome plays in transplant success has been 
underestimated. While gut microbes have been found to directly contribute to allograft rejection, 
they also indirectly regulate many other processes that contribute to the long-term health 
outcomes in transplant patients. Through short chain fatty acid production, they regulate blood 
pressure and cholesterol levels, two conditions that can lead to chronic disease such as type one 
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and type two diabetes, high blood pressure, and irritable bowel syndrome. The importance of 
restoring homeostasis in the gut microbiome is vastly important for long term health outcomes 

















































In looking for ways to improve transplant success, the gut microbiome is a good place to 
start. With emerging evidence that the gut microbiome is involved in many processes, such as 
promotion of angiogenesis and regulation of the immune system, it is reasonable to conclude that 
a patient’s gut microbiome affects solid organ transplant outcome. Transplant success can be 
improved by preventing acute and chronic rejection, but also by preventing infection, chronic 
disease development, and improving mental health, all of which the microbiome influences. 
While the gut microbiome of the patient is primarily involved in determining patient transplant 
outcomes, the donor’s gut microbiome may also have influence on the transplant outcome. This 
section analyzes the possible ways the donor and patient gut microbiomes are affected before 
surgery, how the transplant surgery itself affects the patient’s gut microbiome, and how post-
transplant recovery affects the gut microbiome. The impact of how changes in the microbiome 
before, during, and after transplant affect transplant success immediately and in the long term is 








To understand the different factors affecting patient outcomes pre-transplant it is 
important to consider both living and non-living donors. Living donors can donate a kidney and 
parts of their liver, lungs, pancreas, and intestines while non-living donors can donate those 
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organs in addition to their heart. The role the gut microbiome of a living or non-livings donor 
plays in transplant success is unclear. However, the gut microbiota is known to interact with 
distant organs and play a role in the regulation of many bodily systems. Therefore, disruption to 
the gut microbiome could have a negative effect on procured organs for transplant. In addition, 
deceased donors experience a variety of preoperative interventions that can result in poorer 
transplant outcomes, while the organ itself also experiences preoperative procedures that affect 
graft function post-transplant. 
In solid organ transplantation, the quality of care the donor receives pre-transplant affects 
the recipient’s outcome post-transplant. For instance, if the non-living donor is not properly 
attended to, hormonal and inflammatory changes, hyperglycemia, and increased plasma levels of 
interleukin-6 due to brain death can result in poorer graft utilization, graft dysfunction, and 
increased chances of rejection (Kumar, 2016). Established protocols for donor management 
require that the non-living donor’s temperature, hormone levels, fluids, ventilation, and 
cardiovascular system must all be properly controlled to improve graft function and surgical 
outcomes (Kumar, 2016). In addition, organs procured for transplant from non-living donors are 
in a state of distress due to bodily changes that occur after death. These organs spend more time 
in preservation solution, compared to organs from living donors, before being transferred to the 
recipient. Organ distress and a greater amount of time spent in preservation fluid may reduce 
organ function temporarily and delay the organ from being fully functional after its transplant. 
This has been observed in kidney transplants where the transplanted kidney can take weeks to 
become fully functional after surgery.  
 The role the donor’s gut microbiome plays in affecting transplant outcomes is still not 
well understood, but it seems that it may be of more concern in deceased donors than living 
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donors. Considering living donors, it appears unlikely that the donor’s gut microbiome affects 
the organ transplant. This conclusion was reached by the fact that living donors undergo an 
intense screening process and must be in very good health to become an organ donor. This 
makes it highly unlikely that the living donor is experiencing gut dysbiosis which could 
negatively affect transplant outcomes. However, the microbes on the procured organ itself may 
cause infection, which is true for deceased donors as well. 
Currently, it is not medical practice to treat whole organs with antiseptic solutions to 
eliminate bacterial, viral, or fungal contaminants due to the time constraints of organ viability 
(Block). Hypothermic preservation and the treatment of organs for donation with organ 
preservation solutions can keep microorganisms alive on the donor organs and facilitate their 
growth (Oriol et al., 2018). This is potentially dangerous, especially for lung and skin 
transplants, because the microbes from the donor may be transferred to the recipient and result in 
infection or poorer graft outcome. Despite this possibility, all organ donors undergo meticulous 
preoperative screenings to ensure the absence of infectious agents before organ removal. Also, 
while there is a high incidence of culture-positive preservation fluid, very few preservation fluids 
test positive for pathogenic microorganisms. In addition, it has been found that transmission of 
bacteria from the donor to the recipient is infrequent in deceased donor liver transplantation 
(Chan et al., 2019). Overall, it is rare for a patient to contract infections from the donor organ, 
especially in heart, liver, and kidney transplants as they are sterile organs, but not impossible.  
The deceased donor’s microbiome may be more influential in affecting transplant 
outcomes than the living donor’s microbiome. Most deceased donors are brain dead and when 
brain death is caused by severe brain injury, there is a disruption in the brain-gut axis resulting in 
chronic dysfunction of the gastrointestinal system (Zhu et al., 2019). This was observed in an 
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experiment in which changes were found in the gut microbiota of mice after experimental stroke 
and traumatic brain injury (Zhu et al., 2019). The experiment demonstrated that the brain and the 
gut microbiome have a direct relationship and disrupting it causes stress to intestinal microbe 
communities. Significant changes in the diversity to the microbiota have been observed within 
two hours of traumatic brain injury (Zhu et al., 2019). Depending on the type of injury, brain 
death may occur in minutes or over a period of days. Since changes to the microbiome occur at a 
relatively accelerated rate, it is possible that dysbiosis in the donor’s intestinal microbiome may 
affect the microbes present on organs being removed for organ donation which may impact 
organ function in the recipient after transplant.  
Living donor organ transplants have better outcomes and lower rates of rejection than 
deceased donor transplants. This is partly because living donors are better genetic matches to the 
recipient due to the ability to test potential donors ahead of time and find the most compatible 
patient to match with the donor. Rejection kinetics of transplanted organs are greatly dependent 
on the extent of genetic disparities between the donor and recipient. However, environmental 
factors may affect rejection kinetics too (McIntosh et al., 2018).  
The main environmental factor affecting transplant outcomes is the process of cooling 
organs after removal. This process is essential for keeping the organ viable for transplant. 
Typically, a heart or lung has a six-hour window in which it can be kept viable for transplant 
while a liver will keep for 8-12 hours and a kidney for 24-46 hours (HRSA). New super cooling 
methods have been reported to be able to keep livers stored at sub-zero temperatures without 
freezing which allows the liver to be stored outside of a body for a day and a half and still can 
recover and function properly. While this technology can hopefully be applied to other organs, 
the larger the organ the more difficult the super cooling process is (de Vires et al., 2019).  
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Currently, the method of organ preservation is different for different organs. The basic 
concept behind the method of preservation is the same. All organs are preserved by hypothermic 
preservation using a type of solution specific for the organ. For the liver and kidney, a cold 
storage solution developed at the University of Wisconsin at Madison has proven to be the 
preferred solution while a donated heart uses crystalloid cardioplegia solution (Southard & 
Belzar, 1995). Other solutions such as Celsior solution, Kyoto solution, and Bretschneider’s 
HTK solution can also be used, each having slight advantages and disadvantages over the others.  
The cooling process itself is important because good organ preservation is a major 
determinant of graft outcome after transplant and re-vascularization. Even if the organ is a good 
genetic match for the recipient, the care the organ receives upon removal from a donor is critical 
for maximizing organ function in the recipient.  
 
Recipient: 
The microbiome of a patient awaiting an organ donation is affected by many individual 
and environmental factors. Organ transplant recipients are already suffering from dysbiosis 
because of their need for an organ transplant. The extent of dysbiosis depends on the severity of 
their condition, but can be made worse by other factors such as the hospital environment, pre-
surgery drugs, a lack of exercise, and restricted diet.  
To qualify for an organ transplant, organ recipients must suffer from irreversible and 
otherwise fatal organ failure. The waiting list for an organ transplant can range from a couple of 
months to years, with the longest wait time being around two to five years. The median waiting 
time for high priority candidates is around 2.6 months, while median waiting time for 
intermediate priority candidates is around 8.5 months (Goldstein et al., 2016). Waiting times 
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vary due to blood type, ethnicity, UNOS (United Network of Organ Sharing) status at listing, and 
age. Due to long wait times, patients may be hospitalized for a prolonged amount of time. 
Patients typically wait at home, but are usually in and out of the hospital because of 
complications associated with their condition. In severe cases, patients are kept in the hospital to 
monitor their health status. Extended hospital stays and trips in and out of the hospital can cause 
changes in the gut microbiome as hospitals themselves have been found to be microbial 
ecosystems that facilitate microbe exchange between patients, staff, and visitors who occupy the 
hospital. In fact, the hospital may serve as a vector for infection transmission in extended stay 
patients.  
The Hospital Microbiome Project, one of the largest microbiome analyses undertaken, 
examined how microbial exchange works in the hospital setting. The results of the Hospital 
Microbiome Project showed that on the first day a patient is admitted to the hospital, microbes 
spread from the surroundings to the patient. However, this is quickly reversed by the second day 
when the patient's microbiome colonizes the room, increasing the diversity of the microbes in the 
room. Long term stays have shown that potentially harmful bacteria, including Staphylococcus 
aureus and Staphylococcus epidermidis, acquired antibiotic resistant genes and promoted 
hospital acquired host infections (Wang & Raun., 2017).  
According to Dr. Michelle Wright at the University of Texas School of Nursing, the 
environmental switch from home and hospital is very disruptive to the microbiome. Many 
aspects of the hospital environment affect a patient’s gut microbiome, including, but not limited 
to, encounters with different healthcare providers, the hospital diet, and exposure to antibiotic 
resistant bacteria, known as “superbugs”. 
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In transplant patients, with extended hospitalization prior to transplant surgery, this is 
potentially harmful as they are exposed to these factors for longer periods of time. This increases 
the risk of disruption in the microbiome and the chances of contracting a hospital acquired 
infection. In serious cases, this can put transplant patients at risk for not being able to receive an 
organ if one becomes available. In addition, extended hospitalization affects the patients diet by 
limiting what they can eat to what is available in the hospital. High fiber diets and plant based 
diets have been found to be associated with healthier microbiomes. However, hospitals have 
been criticized for not serving quality nutrient rich food. Recently, the New York state 
Legislature’s Senate Health Committee passed a landmark bill to guarantee hospital patients 
plant-based options (NY State Senate). While the quality of hospital food has been increasing 
over the past decade, dietary switches may induce shifts in the microbiome composition, 
function, secreted metabolites and proliferative and inflammatory markers (Pietzner et al., 2017). 
All food must be prepared and handled properly by all hospital staff to prevent infection before 
surgery. 
Pre-surgery preparation is another factor that disrupts the gut microbiome. Fasting, 
mechanical bowel cleansing and antibiotics are all factors that have only just started being 
examined for their role in gut flora disruption. Medications may affect the composition of the 
microbiome while the microbiome is known to affect pharmacokinetic properties of medications 
and contribute to the effectiveness or side effects of these medications. Prior to surgery, patients 
take antibiotics 30 minutes before their transplant and immunosuppression medications are taken 
a couple of hours before. While antibiotics are known for killing bacteria or preventing them 
from multiplying, immunosuppressants also affect the microbiome. These changes have a greater 
effect after the transplant surgery when immunosuppressants begin to be routinely taken. 
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Immunosuppressants primarily alter the microbiome by reducing many taxa commonly found in 
a healthy microbiome.  
The microbiome is also affected by exercise, patients awaiting transplants may have 
difficulty working out due to their medical conditions, but regular exercise has been found to 
play an important role pre- and post-transplant to increase quality and life and prevent 
development of chronic diseases such as diabetes, de novo tumors, and high blood pressure. A 
low intensity routine preoperative training program for patients awaiting organ transplant has 
great effects on reducing the length of hospital stay and increasing quality of life and general 
robustness (Beekman, Berzigotti, & Banz 2018).  
The patient’s condition and their age are two other factors that influence the intestinal 
microbiome prior to transplant. Relevant to pediatric transplant patients, teenagers going through 
adolescence experience microbiome changes. It is unknown how needing an organ transplant 
affects typical microbiome development, but it is a factor to be considered. Overall, even before 
the transplant surgery, multiple factors are contributing to the disruption of the microbiome and 




Pre-surgery efforts to improve organ transplant outcomes should focus on the deceased 
donors and patients. To improve transplant outcomes, patients should be kept at home and on 
their regular routine as much as possible as environmental changes are known for disrupting the 
microbiome. While this cannot always be done, especially in serious situations, hospital level 
care should be brought to the patient’s home whenever possible to prevent long term stays in the 
hospital.   
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To reduce the length of time solid organ transplant patients spend in the hospital, pre-
transplant exercise can also be a method for keeping patients healthy and at home. Pre-surgery 
exercise is important even though exercise capacity is reduced in solid organ transplant 
candidates. Studies have found that exercise training pre-transplant is safe and should consist of 
aerobic training or a combination of aerobic training and resistance training (Janaudis-Ferreira et 
al., 2019). Pre-transplant exercise increases the exercise capacity of the patient, may positively 
affect gut microbiome composition, and can improve post-transplant outcomes as well. 
Regarding deceased donors, as discussed earlier, the quality of pre-transplant care the 
donor receives affects the recipient’s outcome post-transplant. The time after brain death and 
before organ procurement is a critical period in which organ quality can be affected. While there 
are standard clinical guidelines for maintaining cardiovascular and hemodynamic stabilization, 
there is currently no optimal approach to hormonal replacement in brain-dead donors 
(Ingelfinger, 2018). While thyroid hormones, vasopressin, insulin, and glucocorticoids are 
commonly used, optimizing hormonal replacement therapy in deceased donors is important for 
not only improving transplant outcomes, but also for helping address the major issue of organ 
shortage by increasing the number of organs available for donation.  
Methylprednisolone is a corticosteroid medicine that prevents the release of substances in 
the body that cause inflammation. Studies have found that when methylprednisolone, 
vasopressin, and thyroid hormone are used together to treat deceased donors less graft 
dysfunction and improved early survival were observed in heart transplant patients. 
Methylprednisolone therapy also was found to improve liver function after liver transplant 
(Kotsch et al., 2008). Continuing to understand and improve hormonal replacement in deceased 
donors is important for creating an optimal approach to hormonal replacement therapy that can 
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II. DURING TRANSPLANT 
 
 
Microbes alter their phenotypic expression to optimize fitness by assessing their local 
environment (Rowley et al., 2006). One of the most disruptive events to the intestinal 
microbiome is surgery as it is highly stressful on the body. Surgery alters the gut microbiota 
composition, microbial abundance, and function (Guyton & Alverdy 2017). In a study examining 
the effect of abdominal surgery on piglets, data showed that two weeks after the surgery was 
performed, there was a reduction in microbes of the families Enterobacteriaceae, 
Bacteroidaceae, and Rhodospirillaceae when compared to the control group (Stavrou & 
Kotzampassi, 2016). For the most part, gut flora can adapt to surgical stress. This is evident by 
the fact that most surgical patients do not experience infectious complications post-surgery. 
However, in specific patients, bacteria can sense host stress, humoral alterations, and specific 
environmental cues that result in gut flora becoming virulent and pathogenic (Stavrou & 
Kotzampassi, 2016). This results in post-surgical infections that can be threatening to solid organ 
transplant patients. 
The anesthetic used during the transplant procedure has also been found to alter the 
recipient’s microbiome. In a mouse model, 16s ribosomal RNA sequencing was used to analyze 
the effects of volatile anesthetics on the composition and diversity in the intestinal microbiome 
(Serbanescu et al., 2019). The results showed that after exposure to isoflurane, a general 
anesthetic, the diversity in the gut microbiome decreased. In addition, other good gut bacteria 
were found to be depleted suggesting that volatile anesthetics may contribute to gut microbial 
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dysbiosis in the patient post-surgery (Serbanescu et al., 2019). The relationship between the 
microbiome and use of anesthetics is complicated as the gut microbiome influences 
pharmacokinetic properties which determine the effectiveness and proper dosage of the drugs. 
The gut microbiome must be taken into consideration before an anesthesiology treatment plan is 
created, but at the same time the anesthetics alter the composition of the microbiome. This dual 
relationship complicates the treatment plan for patients and living donors.  
 
Recommendations 
To reduce gut microbiome disruption, it is critical to reduce surgically induced stress. 
Surgical stress impairs metabolism, immune function, and wound healing and can result in 
infection and increased mortality (Finnerty et al., 2013). These are all processes in which the 
microbiome is involved in. Reducing operative stress and host inflammatory responses by 
developing minimally invasive surgical techniques may help reduce post-transplant infections 
and ensure the patient's best outcomes. In addition, the type of anesthesia used during surgery 
may also reduce stress. 
Minimally invasive surgery has been found to improve surgical outcomes and help 
reduce postoperative morbidity. Small incision open surgery, laparoscopic surgery, and robotic 
surgery are all minimally invasive surgical techniques that have been employed in kidney 
transplantation. Recently, the first purely laparoscopic living donor surgery for liver transplant 
was performed (Uwechue et al., 2017). While minimally invasive surgical techniques reduce risk 
of infection and hospital recovery time, they are greatly limited by medical imaging technology. 
Research to develop new imaging technologies that improve image quality and enable 3D color 
visualization as well as real-time tracking devices should be a priority as it has great ability to 
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improve minimally invasive surgery technology and have a positive impact on patient outcomes 
(Goel, 2019). 
Anesthesia also has an effect on reducing stress on the body due to major surgery. Total 
intravenous anesthesia, a general anesthesia technique that provides anesthesia through an 
exclusively intravenous route and does not use inhalation agents, has been found to have a 
positive effect on preventing postoperative inflammation and other stress response mechanisms. 
Epidural anesthesia and general anesthesia are commonly used during kidney transplantation 
(SarinKapoor et al., 2007). However, in kidney transplantation, total intravenous anesthesia can 
be used instead of balanced anesthesia, a general anesthetic technique that uses smaller doses of 
two or more agents (Modesti., 2006). Total intravenous anesthesia has many advantages such as 






After a successful organ transplant surgery, new threats to the gut microbiome arise while 
pre-transplant threats persist. In the days following surgery, patients are still exposed to the 
hospital environment and are limited in their diet and exercise routines. However, this changes 
once patients are discharged and overtime regain dietary freedom and increased ability to 
exercise. However, post-surgery the patient must begin to regularly take immunosuppressant 
drugs to prevent organ rejection. Broad-spectrum antibiotic prophylaxis is also frequently 
prescribed to prevent perioperative complications immediately following surgery.   
Transplant recipients are required to stay in the hospital following surgery to ensure 
proper recovery. Kidney transplant patients typically remain in the hospital for three to five days 
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while liver and heart transplant patients stay in the hospital for about a week before being 
discharged. As discussed previously, the hospital environment, hospital and post-surgery diet, 
and limited physical activity can negatively affect the microbiome of the patient. 
New to the patient after a successful organ transplant surgery is the routine administration 
of immunosuppressive drugs required to prevent acute and chronic rejection. Combinations of 
medications and high doses are prescribed at first and are lowered overtime. The combination of 
drugs varies for the type of organ transplanted and for the individual. Typically, 
immunosuppressive drugs such as Prednisone, Tacrolimus, Cyclosporine, and Mycophenolate 
are prescribed. Immunosuppressive drugs are known to lower the body’s resistance to infection, 
so anti-infection medications are also prescribed as infections can have severe consequences for 
transplant patients. Commonly taken anti-infection drugs include Nystatin, Acyclovir, 
Clotrimazole, and Ganciclovir. Anti-infection medications are usually only taken for one to three 
months after transplant (Umich). Anti-ulcer medications and anti-hypertensive medications may 
also be prescribed and are to be determined by the physician. 
Immunosuppressive drugs, required for transplant recipients, have been found to alter 
microbial community structures. Research shows that bacterial diversity in the gut microbiome 
significantly decreased when treated with immunosuppressive drugs (Baht et. al, 2017). Using 
16s RNA sequencing, the phylogenetic diversity in the intestinal microbiome was found to be 
reduced by Sirolimus, an immunosuppressant taken by kidney transplant patients. Tacrolimus, 
another immunosuppressant prescribed to kidney, liver, and heart transplant patients, and 
Sirolimus were found to alter gut flora by increasing the amount of Lactobacillus and 
Akkermansia muciniphila making the microbiome resemble the microbiome of diabetic patients 
(Zhang et al., 2018).  
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Other taxa that were found to be reduced in immunosuppressed patients were Roseburia, 
Oscillospira, Rothia, Micrococcaceae, and Staphylococcus (Bhat et al., 2017). These taxa are 
butyrate-producing bacteria that are important for maintaining intestinal health and promoting 
insulin sensitivity. In addition to the alterations to the intestinal bacterial profile, rats treated with 
immunosuppressive drugs were found to develop hyperglycemia and increased cholesterol levels 
(Bhat et al. 2017). These results demonstrate the consequences of immunosuppressive drugs in 
transplant patients.  
Like immunosuppressant drugs, antibiotic prophylaxis is prescribed post-transplant, but 
only for 24-48 hours in most cases. Broad-spectrum antibiotic prophylaxis is routinely utilized 
after almost all surgical procedures to prevent postoperative surgical site infections (SSIs) from 
occurring. They decrease the amount of bacteria in the surgical wound to allow for proper 
healing. Surgical site infections are one of the most common healthcare-associated infections 
and, depending on the type of transplant, occur in 3-53% of transplant patients (Anesi et al., 
2018). SSIs are associated with increased graft rejection and mortality of solid organ transplant 
patients. 
Antibiotics eliminate pathogenic bacteria, but also eliminate beneficial bacteria as well. 
The effects on the composition of the gut microbiome varies depending on the type and duration 
of antibiotics taken. Altering the microbiome with antibiotics results in decreasing the metabolic 
potential of the microbiome and makes it easier for pathogenic bacteria to colonize (Rahim, 
Taylor, & Hirota., 2017). Emerging data has shown that antibiotic prophylaxis may increase the 
risk of Clostridium difficile infection and graft-versus-host-disease (Horton, Haste, & Taplitz, 
2018). Ironically, antibiotic prophylaxis which is used to prevent SSIs may increase chances for 





While prophylactic antibiotics decrease the risk of surgical site infections and improve 
morbidity and mortality outcomes, they can cause significant alterations to an already disrupted 
microbiome. Developing other ways to reduce the incidence of surgical site infections that don’t 
cause antibiotic resistance, Clostridium difficile infection, and alterations of the gut microbiome 
should be considered. Using non-absorbable antimicrobials has been found to be successful in 
performing the role of prophylactic antibiotics and do not disrupt the gut microbiome. In 
addition, insulin therapy has been found to decrease rates of post-transplant infection and sepsis.  
Non-absorbable antimicrobials, such as Rifaximin, an antibiotic with broad spectrum 
activity and limited intestinal absorption, have been found to have a negligible impact on the 
intestinal microbiome and decrease gut inflammation while also decreasing transplant mortality 
and improving overall survival rates (Horton, Haste, & Taplitz, 2018). Rifaximin is safe, has 
minimal drug interactions, and is thought to help prevent and act as a therapeutic for other 
gastrointestinal diseases as well (Koo & DuPont, 2010). 
The best way to maintain gut microbiome structure in transplant patients is through 
microbiome profiling and avoiding the use of broad-spectrum antibiotic in individuals with low 
gut flora diversity. Stool samples from patients could be used to gain insight into the diversity of 
their individual gut microbiome and inform physicians on whether broad-spectrum antibiotics or 
narrower-spectrum antibiotics should be prescribed. In addition to examining the gut microbiome 
composition of the patient, the patient’s individual susceptibility to infections due to genetic 
polymorphisms should also be considered. Recent evidence shows that genetic polymorphisms in 
innate immunity are associated with increased risk of bacterial infections after liver transplant 
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(van Hoek, de Rooij, & Verspaget, 2012). This has been found to also be true in heart and kidney 
transplant recipients. The ability to identify these genetic markers through individual genomic 
sequencing can help tailor non-absorbable antimicrobials to the individual patient and improve 
transplant outcomes.  
Hyperglycemia, an abnormally high blood glucose level, is common after extreme 
physiological stress and can be a result of transplant surgery. Optimal insulin therapy could be a 
potential therapy for transplant patients as it has been found to significantly decrease rates of 
infection and sepsis while also improving organ function and helping reverse the post-traumatic 
catabolic state due to surgery (Finnerty et al., 2013). However, the complex conditions of 
transplant patients make it difficult to understand the physiological effects that insulin therapy 
may have on transplant patients (Iestyn et al., 2019). More research must be conducted to 
























I.  Fecal Microbial Transplant  
 
 
Recently, altering the composition of the microbiome has been found to be possible 
through the unconventional method of fecal microbial transplant. Fecal microbial transplant 
(FMT) is a therapy that has been successful in treating recurrent Clostridium difficile (C. diff) 
infection, an infection that leads to severe colon inflammation. FMT works by infusing bacteria 
from a healthy donor’s stool into a patient’s disrupted microbiome. The transplanted bacteria 
repopulate the gut of the recipient with diverse microbes that outcompete the detrimental C. diff 
bacteria. This reverses dysbiosis and restores normal gut function by establishing a new gut 
microbiota in the recipient.  
Fecal microbial transplant has been 90% successful in treating recurrent Clostridium 
difficile infection (Gupta, Allen-Vercoe, Petrof, 2016). The success seen with treating recurrent 
Clostridium difficile infection suggests that FMT could also reset an organ transplant recipient’s 
disrupted microbiome to a healthy homeostatic state. If FMT were to be successful in solid organ 
transplant patients, the rates of post-transplant infection, organ rejection, and development of 
comorbidities would likely decrease. Many researchers have had similar ideas and FMT is 
currently being explored in a variety of clinical settings. Research has seen preliminary success 
in using FMT to treat functional constipation, immunotherapy-induced colitis, neurodegenerative 




Recently, FMT was tested to determine if it could be a successful therapy for treating 
obesity. In a randomized placebo controlled pilot trial, experimental group participants received 
30 FMT capsules followed by 2 doses of 12 capsules over a 12-week period and the control 
group received placebos instead of the FMT capsules (Allegretti et al. 2019). The results showed 
three important things: that FMT was a safe therapy, donor community engraftment occurred, 
and that the stool samples of the participants became more like the stool samples from the FMT 
donor. The study was a mild success, but concluded that a longer follow up needed to be 
conducted to make final conclusions.  
Currently, FMT is not FDA-approved and is considered investigational (Allegretti). FMT 
may be used in clinical trials, but it can only be performed for clinical care to treat recurrent 
Clostridium difficile infection. It is important to note that FMT has been approved for use in 
immunocompromised patients making FMT a possible therapy for restoring the gut microbiome 
in solid organ transplant patients. However, immunocompromised patients are still at high risk 
for infection making donor screening even more critical.  
Even if FMT cannot be used to reverse gut dysbiosis, it can still indirectly improve 
patient outcomes by preventing the development of comorbidities such as obesity and diabetes. 
This reduces the burden of disease and amount of stress put on the transplant recipient resulting 
in a longer lifespan, lower healthcare costs, and less care required to deal with chronic disease. 
The cost of FMT depends on the hospital and the method of administration which can be 
by colonoscopy, enema, nasogastric tube, or capsules. Health insurance does cover components 
of FMT administration. OpenBiome, a nonprofit stool bank, sells FMT capsules for $1950 per 
dose and provides FMT upper and lower delivery microbiota preparations for $1595 per 
treatment. The costs can be up to $3500 if one chooses to use and screen their own donor. In 
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certain situations, FMT must be performed twice to see results, doubling these costs. Most 
insurance companies do cover FMT which helps to reduce the cost burden on the patient.  
FMT also has no known side effects and is a quick outpatient procedure. The entire 
procedure takes around two hours with the transplant portion only taking around 10 minutes and 
patients with C. diff usually recover in 3-4 days. Besides the transplant itself, FMT does not 
require any extra care. From what is currently known about dysbiosis in the human gut 
microbiome in kidney, liver, and heart transplant patients, FMT should be able to be used as a 
potential therapy for all three transplant types.  
A major challenge in fecal microbial transplantation includes strict donor screening as to 
prevent the transmission of multidrug resistance organisms through FMT. Screening protocols to 
detect multidrug resistant organisms and potentially disease causing organisms have been 
implemented in all major stool banks globally (Allegretti). Standardized screening protocols are 
essential for patient safety and increasingly important in immunosuppressed patients (Allegretti). 
In addition to stool screening, uniform protocols for stool preparation need to be established and 
the best method for FMT administration must be determined. Since FMT is a recently discovered 
therapy, these challenges need to be addressed before FMT can be used. 
 It is important to note that while recurrent C. diff infection can be treated with one or two 
FMT treatments, chronic disorders may require more frequent FMT administration over a longer 
period and may not be improved by FMT at all. In addition, recurrent C. diff infection is 
considered a “relatively pure” form of dysbiosis in which FMT from one unrelated donor is 
acceptable (Dupont et al., 2020). For transplant patients with a long history of critical illness 
FMT may not work as well or have a significant impact on the disrupted microbiome. The best 
results of FMT may come from its ability to stabilize short chain fatty acid production, increase 
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Tregs and IL-10 production, stimulate IgA production, and restore the bacteriophage population 




II.  Synbiotic Therapy 
 
 
Gut dysfunction caused by dysbiosis in the intestinal microbiome is a contributing factor 
to disease progression. Under conditions of critical illness such as organ failure it is difficult for 
the microbiome to maintain homeostasis, especially after invasive procedures like transplant 
surgery. Due to their susceptibility to infection transplant patients are at risk of developing 
several complications including ventilator-associated pneumonia, enteritis, systemic 
inflammatory response syndrome (SIRS), and sepsis. Synbiotic therapy has seen some success as 
a potential method for restoring homeostasis in gut microbiota and the overall gut environment.  
Synbiotics are combinations of prebiotics and probiotics that have been found to 
successfully alter the structure of the intestinal microbiome. Prebiotics are high-fiber foods that 
promote the growth of certain colonic bacteria while probiotics are live, non-pathogenic 
microorganisms which may protect the gut barrier, reduce pathogen overgrowth, decrease 
bacterial translocation, and prevent infection (Pickard et al. 2017). When prebiotics and 
probiotics are administered together they work to enhance the survival of probiotic bacterial 
strains and stimulate the gastrointestinal bacteria resulting in a healthier gut (Anderson et al. 
2004). Synbiotics are preferred over probiotics alone because they improve survival of probiotic 
bacteria as it passes through the upper intestinal tract and implant in the colon (Peña, 2007). 
Recent research suggests that synbiotics can improve gut microbial composition and 
increase antioxidant capacity, making synbiotic therapy a promising option to reestablish 
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homeostasis in the gut microbiome (Morshedi, Saghafi-Asl, & Hosseinifard, 2020). A study 
found that synbiotics altered the gut microbiome composition by reducing the amount of 
Clostridium and Bacteroides and increasing the amount of Lactobacillus in the microbiome 
(Morshedi, Saghafi-Asl, & Hosseinifard, 2020). In addition, synbiotic therapy has been found to 
reduce bacterial infection in transplant patients. 
In examining the clinical efficacy of synbiotics in abdominal surgery patients, multiple 
studies have found that in randomized controlled trials, groups treated with probiotics and 
synbiotics saw a reduction in the number of bacterial infections they developed compared to 
patients in groups that did not receive synbiotics and probiotics. These results were observed 
when liver transplant patients in the experimental group were treated with L. plantarum 299v, a 
probiotic (Rayes et al., 2002). The results showed that 13% of those who received the treatment 
had infectious complications. This was a significant difference when compared to the control 
group in which 48% had infectious complications (Rayes et al., 2002). Another study showed 
that in liver transplant patients treated with the synbiotic Synbiotic2000, 3% of the experimental 
group had infectious complications while 48% of the control group had infectious complications 
(Rayes et al., 2005). A study in living liver transplantation patients showed that patients in the 
experimental group who received BLO, a synbiotic, had 4% infectious complications while the 
control group had 24% infectious complications (Eguchi et al., 2011). These results conclude 
that preoperative administration of probiotics and synbiotics results in a decrease in infectious 
complications and can improve the health of transplant patients (Shimizu et al., 2013).  
Synbiotic treatment has also seen positive outcomes in preventing complications in 
patients with sepsis, a life-threatening condition caused by the body’s extreme response to 
infection (Zeratsky). Solid organ transplant recipients are at a higher risk for sepsis than the 
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general population due to their immunocompromised state (Donnelly). Sepsis can be a 
complication of ventilator-associated pneumonia, which has been found to be the main cause of 
infection following heart transplant and major heart surgery (Hortal et al., 2009). Methods of 
reducing the incidence of infection and sepsis are crucial and would have a major impact on the 
mortality rate due to sepsis.  
 Administering synbiotics to septic patients as a drug therapy showed positive results in a 
study that aimed to evaluate how effective symbiotics are at modulating the gut microbiome and 
in reducing complications in patients with sepsis. Incidences of enteritis and ventilator-associated 
pneumonia were significantly lower in the cohort that received synbiotic therapy than in the 
control group (Shimizu et al., 2013). Higher rates of Bifidobacterium and Lactobacillus, the most 
common probiotics, and higher levels of organic acid concentration were seen in the group who 
received synbiotic treatment when compared to the control group (Shimizu et al., 2013). The 
study concluded that synbiotics were effective at modulating the gut microbiota and could have 
preventative effects on the rates of ventilator-associated pneumonia and enteritis (Shimizu et al., 
2013). Symbiotics also showed a decrease in septic complications in patients with systemic 
inflammatory response syndrome (SIRS) proving that through intestinal microbiota maintenance, 
septic complications in patients with SIRS can be significantly reduced (Shimizu et al., 2013).  
Due to solid organ transplant recipients’ high risk for infection, implementing synbiotic 
therapy before and after the transplant surgery could be beneficial to prevent enteritis, ventilator-
associated pneumonia, SIRS, and other outcomes of sepsis. Synbiotics also provide a way to 
reduce the use of antibiotics to treat these infections which can reduce multidrug resistance and 
further damage to gut flora. In addition, synbiotic therapy may help reduce rates of organ 
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rejection because of its ability to modulate the composition of the intestinal microbiome and 
reduce septic complications in SIRS patients who are at increased risk for organ failure. 
There is a lack of evidence for using probiotics and synbiotics to treat most health 
conditions. This has resulted in the FDA not yet approving symbiotic therapies to treat health 
problems (Wu, Chen, & Huang, 2017). However, 74 clinical studies found that synbiotic 
administration was safe in children as well as adults (van den Nieuwboer et al., 2015).  
In terms of cost, there have not been any studies that have analyzed the cost of synbiotic 
therapy as it is relatively new. Studies to test the cost-utility of synbiotic therapy need to be 
conducted, but can only be conducted after synbiotic therapy has been approved and used widely 
to treat dysbiosis in the gut microbiome. An analytical study that analyzes quality-adjusted life-
years, costs (US dollars), and cost per infection avoided would be necessary to analyze the cost-
effectiveness of synbiotic therapy. The amount of care required in implementing the use of 
synbiotics pre- and post-transplant is relatively low. Patient’s would have to monitor when their 
synbiotics were taken, if the correct dosage was taken, and that the prescription gets refilled.  
Symbiotics appear to be beneficial to kidney, liver, and heart transplant patients. In 
kidney patients, synbiotics have an extra benefit of being effective at lowering concentrations of 
p-Cresol, a uremic toxin that is typically elevated due to the disrupted microbiome (Guida et al., 
2017). In liver transplant patients, probiotics containing Lactobacillus with the use of prebiotics 
were found to be effective in reducing infectious complications post-transplant (Jorgensen et al., 
2018). Heart transplant patients would also benefit as they frequently contract infections, one of 
the main causes of mortality in the heart transplant patient population. Overall, synbiotics have 
been found to be effective in reducing the amount of potentially pathogenic microorganisms in 
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the gut microbiome, eliminating potential toxins, providing antioxidants and nutrients through 
fermentation, and stimulating the immune system (Bengmark, 2004). 
Although the results of these experiments support the use of synbiotic therapy and 
highlight its benefits, there are still challenges facing the implementation of synbiotic therapy. 
The biggest of these challenges is that the mechanism of how synbiotics act in the 
gastrointestinal tract remains unknown. It is hypothesized that synbiotics work by increasing the 
abundance of beneficial bacteria, such as Bifidobacterium and Lactobacillus, resulting in an 
increase in the production of short chain fatty acids in the gut. Short chain fatty acids play an 
important role in maintaining intestinal homeostasis and gut flora maintenance and may also 
signal through cell surface G-protein coupled receptors to activate signaling cascades that control 
immune function, therefore enhancing the immune system (Venegas et al. 2019). However, 
further clinical research must be performed to understand the mechanisms of immune responses 
involved in synbiotics’ therapeutic effect on the microbiota. This information is critical in 
determining the effectiveness of synbiotic therapy, when it should be prescribed, and how often 
synbiotics need to be taken by the patient.  
 
 
III.  Short Chain Fatty Acid Supplementation 
 
 
A disrupted gut microbiome is characterized by a decreased abundance of beneficial taxa. 
Lachnospiraceae, Ruminococcaceae, and Clostridium are all bacteria that through bacterial 
fermentation of indigestible fiber produce short chain fatty acids (Needell et al., 2017). Short 
chain fatty acids are important metabolites that work to maintain intestinal homeostasis. Acetate, 
propionate, and butyrate are short chain fatty acids that are key contributors in regulating the gut 
microbiota-epithelium interaction (den Besten et al., 2013). They help maintain gut homeostasis 
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by interacting with metabolite sensing G protein-coupled receptors on endothelial cells (den 
Besten et al., 2013). Decreased production of short chain fatty acids can lead to a rise in gut pH 
further causing damage to the gut flora and infectious complications (Shimizu et al., 2013).  
A lack of microbiota-generated short chain fatty acids is linked to comorbidities such as 
obesity, type one and type two diabetes, cancer, and inflammatory bowel disease (Li, 2020). This 
is dangerous as transplant patients are at higher risk for developing these comorbidities.  
Short chain fatty acid supplements can help compensate for the reduction of short chain fatty 
acid production due to gut flora disruption. By restoring proper levels of short chain fatty acids 
through supplements, metabolic balance can be restored to the gut microbiome. Short chain fatty 
acids have been found to be successful in reshaping the intestinal microbiome by reducing the 
abundance of Clostridium and Bifidobacterium bacteria (Needell et al., 2017) 
While short chain fatty acids have seen some success in directly altering the gut 
microbiome composition, they have also had success in affecting enteroendocrine hormones, 
glucose homeostasis, and colon inflammation (Koh et al., 2016). The short chain fatty acid 
propionate has been found to play an important role in regulating appetite. Long term 
supplementation with colonic propionate has been found to prevent weight gain by releasing 
peptide YY (PYY) and glucagon like peptide 1 (GLP-1) from colonic cells (Chambers et al., 
2016). Supplementation with propionate over a seven-week period resulted in reduced fasting 
glucose levels and increased insulin release in women (Venter et al., 1990). In addition, it has 
been proposed that short chain fatty acids play a role in preventing chronic inflammation, a risk 
factor for colorectal cancer (Koh et al., 2016). However, in considering the effects short chain 
fatty acids have on cancer, other factors such as genetic background, cellular energetics, and 
environmental context must be considered.  
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Short chain fatty acids supplements such as sodium butyrate and inulin-propionate ester 
are FDA approved and are commercially available. Costs around $30-50 dollars for a bottle of 
supplement pills. Kidney, liver, and heart transplant patients would benefit from short chain fatty 
acid supplements because of their anti-inflammatory properties and immune system regulation.  
An issue with short chain fatty acid supplements is that they may be absorbed before they 
reach the colon, thus preventing the colon from benefiting from the supplement. Butyrate has 
been found to best reach the colon when it is fermented from fiber, so increasing the amount of 
high fiber foods in a transplant patient’s diet post-transplant may provide a better result and be 
more cost effective than short chain fatty acid supplements. Butyrate production can be 
stimulated by supplementing one's diet with carbohydrates that can only be degraded by bacteria 
in the colon. However, fiber degradation does not always lead to butyrate production, so to 
improve the results of dietary supplements they may need to be personalized to one’s individual 
gut microbiota. In addition, the route of delivery could play a role in the effectiveness of the 
supplement. Proper route of administration is important because exogenously administered short 








Diet has been found to have a significant impact on microbial composition and gut 
health. Many patients waiting for an organ transplant suffer from malnutrition which increases 
their risk of contracting infections. Despite a lack of studies investigating the gut microbiota in 
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malnourished adults, malnutrition and the gut microbiome have been well studied in children. In 
regards to severe acute malnourished children and their gut microbiome, a malnourished 
microbiome has decreased diversity, is depleted of anaerobic species, and is enriched with 
aerobic species (Tidjani Alou et al., 2017). Restoring the microbiome may not be done through 
diet alone, but it is an important factor nonetheless.   
Up to a fifth of kidney transplant patients suffer from malnutrition (Nolte Fong & Moore, 
2018). The prevalence of malnutrition in cirrhosis, the end stage of many liver diseases, is as 
high as 65%–90% (O’Brien & Williams, 2008). The role that gut microbes play in severe 
malnutrition is not yet understood. However, malnourished patients have higher rates of 
morbidity which decreases organ transplant utility. Nutrient repletion in patients before 
transplant surgery can improve transplant outcomes.  
Malnourished patients are more susceptible to infection which is dangerous pre- and post-
transplant. Severely malnourished liver transplant patients have been found to be at higher risk 
during surgery, required more blood products during the transplant, and had longer postoperative 
hospital stays (Stephenson et al., 2001). Data from this study showed that nutrient repletion in 
patients with end stage liver disease before transplant surgery could help improve transplant 
outcomes. However, nutrient repletion in end-stage liver disease patients can be complicated 
especially since liver disease and kidney disease patients are limited in what they can and cannot 
eat. Attempting to replete protein losses may result in aggravating hepatic encephalopathy and 
increasing carbohydrates can lead to hyperglycemia (Hammad et al., 2017). While there are a 
multitude of factors controlling nutritional status in malnourished liver disease patients, it has 
been suggested that aggressive nutritional support consisting of sufficient intake of vitamins, 
dietary supplements, and trace minerals should be taken by all liver transplant patients pre-
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transplant (DiCecco et. al., 1989). Establishing a healthy diet pre-transplant helps prevent 
malnutrition progression post-transplant.  
A solid organ transplant recipient’s post-transplant diet needs to focus on addressing 
malnutrition and micronutrient deficiencies and take precautions to prevent infection. The post-
transplant diet is a short-term diet that must be re-evaluated after lost energy stores have been 
replenished. The post-transplant diet is replaced by a long-term diet that still focuses on 
preventing infection, but now aims to prevent chronic disease such as diabetes and obesity.  
Weight gain can be an issue for many patients post-transplant due to increased freedom 
with their food and increased appetites due to new medications. This is dangerous for the patient 
because they are at an increased risk for metabolic abnormalities such as obesity, dyslipidemia 
and diabetes. Transplant medications may increase blood pressure and fluid retention, so salt 
should be limited to prevent high blood pressure. Fat should also be controlled to maintain a 
healthy weight and not put stress on the heart. All organ transplant recipients must consult with a 
dietitian to make sure they are eating properly to maintain a healthy weight and not put stress on 
their new organ. Eating a healthy, well balanced diet that includes carbohydrates, protein, and 
fats, and ensuring that foods are prepared properly with no raw or undercooked meat or fish will 
decrease the chances of complications and infections arising after transplant, promoting a healthy 
microbiome. 
In terms of challenges and cost, tailoring a diet to one’s individual needs requires a 
dietitian who is usually provided by hospitals as part of the transplant care team. Overall, altering 
one’s diet is a low-cost method for altering the gut microbiome and can be done by the transplant 
patient themselves with a dietician's help. Consistently keeping a well-balanced diet is likely to 
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encourage a successful transplant and many health benefits like increased short chain fatty acid 
production as previously discussed. 
 
Exercise: 
The effect of exercise on the gut microbiota has been observed in human longitudinal 
studies. These studies show that exercise has an independent impact on microbiome function and 
composition. Consistent aerobic exercise was also seen to have a beneficial impact on the gut 
microbiome. However, long term high intensity aerobic training is likely required to see 
significant taxonomic and metagenomic changes in gut microbiota (Mailing et al., 2019). 
Exercise programs that are of the right intensity, frequency, and target the specific needs of an 
individual have been found to be beneficial for solid organ transplant patients.  
Exercise is important post-transplant because it has been proven to uniquely change the 
composition of the gut microbiome independent of diet. In a twelve-week experiment, mice in 
the exercise group were found to have a unique microbiome where Faecalibacterium, 
Clostridium, and Allobaculum were all present (Yeager, 2019). Faecalibacterium, Clostridium, 
and Allobaculum were absent in the fecal samples collected from the mice who did not exercise. 
The study also found that despite eating a high fat diet, the mice who exercised did not 
experience inflammation in their intestines compared to the mice who did not exercise and did 
experience inflammation.  
When the mice stopped exercising, the gut microbiome changed and reverted to the 
baseline composition. Similar results were seen in a human study in which lean, sedentary people 
enrolled in an exercise program for six weeks developed high levels of Clostridiales, 
Lachnospira, Roseburia, and Faecalibacterium in their gut increasing gut diversity and making 
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their microbiome unique (Yeager, 2019). These two studies corroborate the theory that exercise 
results in distinct gut microbiome changes. 
Much remains unknown about the gut-exercise connection, but there are a couple 
hypotheses on the influence of exercise on the gut microbiome. One hypothesis is that during 
exercise, bile acid and lactate circulation increases resulting in a change in pH of the gut 
therefore shifting the composition of the gut microbiome (Yeager, 2019). Another idea is that 
exercise increases the number of microbes that produce butyrate, a short chain fatty acid that 
promotes homeostasis in gut microbiota. Exercise has also been thought to alter gene expression 
of immune cells in gut tissue resulting in the production of more anti-inflammatory cell-signaling 
proteins and antioxidant enzymes (Allen et al., 2018). The immune cells may promote growth of 
butyrate-producing bacteria and produce more antimicrobial compounds that regulate gut 
microbe composition. While these mechanisms are only theories as to how exercise impacts the 
gut, the many proposed mechanisms imply that there are multiple pathways that link exercise 
and gut health. 
Many patients suffering from end-stage kidney disease, end-stage liver disease, and heart 
failure before organ transplant can participate in exercise training that positively impacts 
transplant outcomes in other ways besides diversifying the microbiome. One of the major 
impacts exercise has on patients pre-transplant, is that it makes patients stronger for surgery. 
End-stage kidney disease patients benefit from a variety of training programs including aerobic 
training, resistance training, and a combination of both. The American Society of Nephrology 
reported that, when compared to standard care, a 12-month program of exercise-based 
rehabilitation significantly slowed the rate of kidney function decline and improved cardio-
respiratory fitness, making patients stronger for a transplant operation (ASN). Patients with 
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cirrhosis, the end stage of many liver diseases, have benefitted from exercise programs that target 
their specific needs and are of the right intensity and frequency as to not put stress on the body 
and liver. Exercise training in patients with stable heart failure have also resulted in positive 
outcomes such as fewer cardiac events and lower rates of hospital readmission due to heart 
failure (Piña et al., 2003).  
Post-transplant, exercise plays an important role in maintaining a healthy lifestyle for 
transplant patients. In kidney transplant recipients, uremic sickness also known as hemolytic-
uremic syndrome (HUS) is increasingly common post-transplant due to several risk factors that 
stem from kidney disease (Remuzzi & Ruggenenti, 1995). HUS can occur in patients who have 
never suffered from uremic syndrome before (de novo post-transplant HUS) or in patients whose 
end stage kidney failure was due to uremic syndrome (recurrent post-transplant HUS). De novo 
HUS is usually caused by either infections or immunosuppressive drugs such as calcineurin 
inhibitors and infections, while recurrent post-transplant HUS occurs in patients who usually 
have a genetic predisposition for the disease. Patients with uremic sickness are at an increased 
risk for cardiovascular events due to accelerated atherosclerosis, a disease in which fatty material 
is deposited on the inner walls of arteries (Rafieian-Kopaei et al., 2014). Accelerated 
atherosclerosis can occur in native arteries of a transplant recipient as well as in the arteries of a 
transplanted heart or kidney (Fellström et al., 1998). Cardiovascular events are a main cause of 
death in pre- and post-transplant patients (Romano, Lorenzon, & Montanaro, 2014).  
Exercise has been found to be a key factor in reducing cardiovascular risk and increasing 
graft function. Multiple studies have found that physical training improves graft function, quality 
of life, and multiple factors related to increased cardiovascular risk such as glomerular filtration 
rate, arterial pressure, and homocysteine levels (Romano, Lorenzon, & Montanaro, 2014). 
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Furthermore, exercise increases cardiovascular function and oxygen delivery to the transplanted 
organ, thus improving graft function. Hypertension in kidney patients is reduced because of 
exercise decreasing arterial pressure augmentation (Romano, Lorenzon, & Montanaro, 2014). 
Levels of homocysteine, an amino acid related to higher prevalence of cardiovascular disease 
seen at elevated levels in kidney organ transplant recipients, are also significantly decreased with 
routine exercise (Romano, Lorenzon, & Montanaro, 2014). Anxiety and depression are reduced 
because of exercise which improves the patient’s mental state and overall health. 
The intensity and duration of exercise has been found to have an impact on health 
outcomes. High intensity interval training has been found to have better results in terms of 
maximum oxygen uptake and systolic blood pressure compared to moderate exercise. Stable 
heart transplant recipients benefited more from high intensity interval training than moderate 
training. The high intensity interval training group had a 17% increase in maximum oxygen 
uptake compared to the moderate exercise group which saw a 10% increase in maximum oxygen 
uptake (Dall et al., 2015). In addition, the systolic blood pressure of the high intensity interval 
training group decreased considerably compared to the moderate exercise group (Dall et al., 
2015). 
Consistent exercise post-transplant appears to be an important low cost, easy to 
implement, and effective therapy for stabilizing the microbiome and promoting whole-body 
health in all solid organ transplant patients. All exercise routines must be approved by a patient's 
transplant team and transplant patients need to be extra cautious about exercising outside, due to 
increased chances of skin cancer caused by immunosuppressive drugs.  
Limitations on physical activity resulting from organ failure may prevent patients from 
using exercise to alter the composition of their gut microbiome pre-transplant. However, pre-
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transplant exercise can still improve patient outcomes by affecting the mental state of the patient, 
improving cardio-respiratory fitness, and making the patient stronger for surgery, therefore 
increasing transplant success. Besides improving gut microbiome diversity, post-transplant 
exercise has many benefits for patients, including preventing chronic disease development such 
as inflammatory bowel disease, obesity and metabolic disease, and mental illness. Tailored 
exercise programs are necessary for all types of transplant patients to foster post-transplant 
health. Physicians must emphasize the importance of consistent exercise to transplant patients, 
empower the patient to exercise consistently by helping them to design a workout program, and 
inform the patient on how to exercise safely. 
 
 
V.  A Change in Perspective: A Sub-Specialized Transplant ICU 
 
Caring for solid organ transplant patients pre- and post-transplant is demanding, complex, 
and requires a multidisciplinary approach. The rigorous management of solid organ transplant 
patients presents challenges to the healthcare team at every stage of the transplant process. 
Establishing a sub-specialized ICU with a collaborative leadership model to tend to the critical 
needs of solid organ transplant patients would allow for more collaborative multidisciplinary 
care and provide an environment to better understand the dynamics of the microbiota in the 
transplant population (Sakpal et al., 2018).  
 The need for a sub-specialized transplant critical care unit is evidenced by the increasing 
number of patients requiring ICU care before and after transplant surgery. In the pre-transplant 
process, numerous complications can arise that jeopardize the patient’s eligibility to receive a 
lifesaving organ. While on the transplant waitlist, end stage kidney disease patients can 
experience renal failure that must be diagnosed and treated appropriately (Lata et al., 2016). 
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Patients suffering from end stage renal disease and who are on the renal transplant waitlist are at 
high risk of contracting catheter-related bloodstream infections, a common infection among 
patients receiving hemodialysis (Lata et al., 2016). There are many other complications that can 
occur in patients waiting to receive an organ donation that can result in them becoming ineligible 
for transplant. Thus, it is imperative to the patients to receive personalized care by multiple 
specialists who understand the patient’s pathophysiology and can curate aggressive therapies to 
ensure their eligibility for solid organ transplant.  
In addition to complications that can occur pre-transplant, the complications that get the 
most attention are the ones that arise post-transplant. Acute and chronic post-transplant 
complications arise more often than expected. Bacterial, viral, and fungal infections may be 
acute or chronic complications while malignancy, cardiovascular disease, chronic rejection, and 
post-transplant diabetes mellitus are common chronic complications. The incidence and severity 
of post-transplant complications requires a multidisciplinary approach to successfully attack 
these issues head on.  
The sub-specialized transplant critical care units would have experienced specialists and 
an intensive care team to provide complex and interdisciplinary care. While many hospitals have 
surgical intensive care units, few have specific transplant surgical intensive care units that cater 
to only transplant patients. This is inadequate because, after transplant surgery, many patients' 
conditions require intense care and resources available in the ICU. In liver transplants, 45.7% of 
patients require immediate ICU stay after transplant surgery (Sakpal et al., 2018) and up at 35% 
return due to infection, graft failure, septic complications, and cardiopulmonary dysfunction 
(Sakpal et al., 2018). After kidney transplants, between 6.6% and up to 20% of patients needed 
to stay in the ICU after surgery. It’s important to note that these statistics underestimate the use 
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of the ICU by solid organ transplant patients because they fail to account for patients who get 
admitted to the ICU with an acute illness and recover, those who pass away in the ICU without 
their status being upgraded, and those who are admitted to the ICU for a condition that causes 
them to be removed from the transplant wait-list (Sakpal et al., 2018).  
The sub-specialized ICU would utilize a transplant and intensive care physician 
collaborative leadership model to provide multidisciplinary practices and processes for organ 
transplant patients. The sub-specialized ICU would operate on a closed ICU model as closed 
ICUs have been reported to have better evidence based management, more effective utilization 
of resources, fewer complications, lower mortality rates, and typically shorter ICU stays (Hanson 
et al., 1999). In a closed ICU model the intensivist, a physician who specializes in the 
pathophysiology of the critically ill and acts as the primary care physician of the ICU, is 
primarily responsible for the treatment and care the patient receives in the ICU.  
The collaborative leadership model encourages collaborative efforts among physicians in 
different specialties and ICU physicians to curate therapies for transplant ICU patients. 
Collaborative efforts between specialists, including but not limited to, critical care, pulmonology, 
anesthesiology, nephrology, neurology, hematology, and gastroenterologists can improve the 
care of solid organ transplant patients. With our incomplete understanding of what is “normal” 
for the intestinal microbiome and how communities of microbes interact and play together, 
having a diverse care team, including gastroenterologists and neurologists, would likely improve 
patient outcomes. Social workers and palliative care specialists are also essential to help patients 
deal with the burdens of solid organ transplant and those who have exhausted treatment options.  
Overall, the sub-specialized transplant critical care unit would work to ensure that 
patients remain eligible to receive organ transplants and care for the patient before and after their 
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surgery. Having an interdisciplinary team of specialists to coordinate therapies are treatment 
plans for patients would result in increased welfare of individual patients and understanding of 
modern surgical critical care for complex solid organ transplant patients (Wolffe, Hugenholtz, 
Wiersinga, 2018).  
As the dynamics of the microbiota have yet to be fully understood, developing and 
determining what targeted therapies, such as synbiotic therapy, fecal microbial transplant, and 
short chain fatty acid supplementation are best to restore the microbiome is difficult. Even once 
the mechanism of how the gut microbiome modulates health in conditions of critical illness, 
individual differences must also be considered. A sub-specialized transplant ICUs in select 
hospitals provides collaborative multidisciplinary care that can focus on individual needs and 
treatments.  
While this is the most expensive and demanding in terms of care potential solution for 
altering the gut microbiome and reducing allograft rejection in solid organ transplant patients, it 
may provide the most benefit in the long term if it is used as a space in which information on 
how to best restore the microbiota and understand the exact mechanism in which the gut 
microbiome effects transplant health can be studied. To do this, transplant patients in the sub-
specialized ICU should be monitored over the course of their ICU stay and transplant procedure 
as well as in the years following. Due to the individual variations in gut flora, recording and 
mapping longitudinal changes in the microbiota for a specific patient may be more informative 
than making inter-individual comparisons (Rahim, Taylor, & Hirota., 2017). This information 
will help physicians understand which targeted approaches, such as the use of synbiotics, FMT, 




Chapter 4: Conclusions and Final Recommendations 
 
 
The human gut microbiome profoundly influences health and disease. This has been 
observed in solid organ transplant patients who experience gut dysbiosis due to their critical 
illness and many factors involved in the solid organ transplant process. Dysbiosis of the gut 
microbiome has been found to be a variable involved in influencing organ rejection, infection, 
and chronic disease development. In a world in which organs for transplant are limited and 3D 
bioprinted organs are still in early stages of development, increasing transplant patient outcomes 
is essential for maximizing the utility of the donated organ.  
Throughout this thesis, factors that may negatively affect a patient’s gut microbiome, 
from the time they are put on the organ waitlist to post-transplant recovery, were identified and 
recommendations were made on how to reduce their impact. In the pre-transplant phase, 
disruptions to the gut microbiome have mainly been associated with environmental changes and 
medications taken by patients. Environmental changes affect patients who require extended 
hospitalization prior to their transplant surgery. Many aspects of the hospital environment can 
have a role in microbiome disruption including encounters with multiple healthcare providers, 
limited exercise and diet, and exposure to antibiotic resistance bacteria. Reducing the amount of 
time patients spend in the hospital and bringing hospital level care to the patient’s home 
whenever possible appears to be the best solution to this problem along with ensuring that the 
patient is engaging in exercise training which is known to promote microbiome health, decrease 
length of hospitalization, and improve surgical outcomes.  
While most transplant candidates are not hospitalized for extended periods of time, all 
transplant patients are required to take medications for their critical illness. The composition of 
the gut microbiome has been found to be altered by many types of drugs such as the phosphate 
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binder lanthanum carbonate, taken by patients suffering from kidney failure, which decreases gut 
microbial diversity. The quality of care the organ donor receives is also influential in the 
recipient’s outcome post-transplant and optimizing hormone replacement therapy in brain-dead 
organ donors has potential for improving transplant outcomes.  
During the transplant surgery, the largest contributor to gut microbiome disruption 
identified was surgical stress. In many patients, gut flora can adapt to surgical stress. However, 
sometimes bacteria can sense host stress and environmental cues that results in gut bacteria 
becoming virulent and pathogenic. Developing minimally invasive surgical techniques through 
research focused on improving image quality, enabling 3D color visualization, and the invention 
of real-time tracking devices would improve minimally invasive surgery technology. Reduction 
of surgically induced stress can also be affected by the type of anesthetic used during the 
surgery. 
In the post-transplant phase, immunosuppressant drugs and antibiotics are new factors 
introduced to the transplant patient that are known to alter gut microbiome composition. The use 
of non-absorbable antimicrobials has been found to have a negligible impact on the gut 
microbiome composition. In addition, microbiome profiling is a technique that can inform 
physicians on what type of antibiotics should be prescribed to an individual post-transplant based 
on individual genetic differences.  
By identifying potential factors that affect the gut microbiome before, during, and after 
solid organ transplant, and making recommendations on how to reduce gut microbiome 
disruptions during these stages of solid organ transplant, efforts to improve transplant outcomes 
by decreasing gut microbiome disruption may focus on these suggested areas. Other potential 
pharmacological and nonpharmacological methods for resolving gut dysbiosis including fecal 
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microbiota transplant, short-chain fatty acid supplementation, synbiotic therapy, dietary and 
exercise changes, and the creation of a sub-specialized transplant ICU were analyzed for their 
potential success in altering the human gut microbiome, preventing organ rejection, and chronic 
disease development in transplant patients.  
The analysis of five potential methods for restoring homeostasis to the microbiome 
suggests that as of now, there is not enough information to determine which of the proposed 
methods would be the most successful for liver, kidney, and heart transplant patients. In all the 
studies conducted using fecal microbial transplant, synbiotic therapy, and short chain fatty acid 
supplementation, researchers found that further study is required to determine if these treatments 
would be useful as a method of helping restore the microbiome to homeostasis and aid in 
preventing graft rejection and the development of chronic disease in transplant patients. In 
addition, more research must be conducted to determine which individuals would benefit from 
these potential therapies as it is likely that the effectiveness of these methods depends in part on 
the individual variation of the gut microbiome. The creation of a sub-specialized transplant ICU, 
a nonpharmacological intervention that was examined, is likely to help with this effort by 
providing an environment to better understand the dynamics of the microbiota in the transplant 
population while also providing collaborative care for patients.  
As mentioned multiple times, one of the biggest obstacles to better understanding how 
the gut microbiome interacts with therapies is the large interpersonal variation of the gut 
microbiota. The unique differences in an individual's gut flora mean that a universal cure for 
restoring gut homeostasis in all individuals is unlikely. Diet and exercise adjustment is a low cost 
and safe nonpharmacological strategy for all patients, but patients may require other therapies, or 
a combination of therapies, depending on individual differences in microbial structure and the 
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various types of gut dysbiosis. While synbiotic therapy, fecal microbial transplant, and short 
chain fatty acid supplementation may each show success in altering gut microbe composition by 
themselves, the outcomes of these therapies would likely be aided by adherence to a well-
balanced diet and routine exercise. 
Both diet and exercise are known to have important roles in maintaining healthy gut 
microbiome compositions and are important for good gut health. Diet is heavily monitored 
throughout the entire transplant process and there are strict dietary guidelines instructing patients 
on what they should be eating before and after their transplant surgery. Kidney transplant 
patients on dialysis are restricted in their diets, liver transplant patients need adequate nutritional 
support as liver failure can cause malnutrition, and heart transplant patients must maintain a low 
sodium diet. After solid organ transplantation, the importance of maintaining a well-balanced 
diet is emphasized by physicians when they converse with patients about life post-transplant. 
However, exercise training guidelines are not well defined for transplant patients throughout the 
transplant process because of insufficient evidence to define specific exercise training guidelines 
for pre-transplant candidates.  
While research shows that exercise is beneficial and safe for transplant patients before 
and after their transplant surgery, the inability to define specific guidelines on the frequency, 
intensity, and length of exercise programs negatively impacts patients who would benefit from 
understanding how they should be exercising and participating in an exercising training program 
pre-transplant. Physical therapists, who play an important role as part of the transplant team, are 
most involved after transplant as exercise training is emphasized in the post-transplant phase. 
Many people find it surprising to learn that kidney, liver, and heart transplant candidates can 
exercise before their transplant surgery and patients may be scared to exercise pre-transplant due 
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to fear that it will exacerbate illness and make their condition worse. Lack of information about 
pre-transplant exercise creates a need for pre-transplant exercise training guidelines that would 
communicate to patients that exercise pre-transplant is safe and allow patients to improve their 
transplant outcome by improving their exercise capacity, strength, mental health, and quality of 
life. More research on pre-transplant exercise is needed to create well defined guidelines for 
patients, but doing so could have great benefits for all patients.  
As more evidence emerges demonstrating that the microbiome regulates the intestinal 
immune system and is involved in transplant success by playing a role in preventing acute and 
chronic rejection, infection, chronic disease development, and improving mental health, it is 
critical that gut microbiome health is prioritized throughout the transplant process. Thinking 
critically about how the microbiome is affected during the transplant process and taking steps to 
eliminate and minimize factors that disrupt gut flora as well as increasing research into how 
interpersonal gut microbiome variation affects therapies such as fecal microbial transplant, short-
chain fatty acid supplementation, and synbiotic therapy is important for understanding how to 
resolve gut dysbiosis and potentially improve outcomes for transplant patients.  
Other nonpharmacological interventions such as diet and exercise changes and the 
creation of a sub-specialized transplant ICU may have important roles in improving health and 
gut microbiome composition and increasing our understanding of the role the gut microbiome 
plays in transplant success respectively. Focusing research on exercise training pre-transplant 
will be beneficial in helping create guidelines for exercise training which communicates to 
patients that exercise pre-transplant is safe and may improve their surgical outcome by 
improving their exercise capacity, strength, mental health, and quality of life. Physical therapists 
who are already included in the transplant team can help take on this role and work with patients 
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before and after surgery to develop a manageable exercise training program for each individual 
patient. This is likely to help improve gut microbiome composition during the pre- and post-
transplant phase for all transplant patients while fecal microbial transplant, synbiotic therapy, and 
short chain fatty acid supplementation are therapies that may only benefit specific individuals 
based on gut microbiome variation. 
While there is a long way to go in understanding the gut microbiome’s role in solid organ 
transplantation and how to manipulate it for long term transplant success and improved patient 
outcomes, the manipulation of the gut microbiome as an immune-modulating therapy should 
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